Research Needs

The following list of research opportunities reflects areas of unmet research need within respiratory and allergic airways disease that real-life research methodologies (observational studies and pragmatic trials) are well positioned to address. It is intended as a dynamic list of research opportunities that have been identified by REG’s expert members and working groups as having important value to the field. All investigators responding to one of the research needs will be eligible for a complimentary review of their study protocol by the expert, independent Anonymised Data Ethics and Protocol Transparency (ADEPT) Committee, which convenes under the auspices of the REG.

Where the REG is currently responding to the identified research gap, relevant links to REG’s activities have been provided.

Tag allows you to search by research need, as listed below. Each need is divided into categories that allows you to view projects by status. You may search with either or both of these parameters, or type a keyword into the search box to find relevant projects from REG.

If you’re looking for a project for your own research, you can filter by proposed projects and use the keyword option to narrow your search. Contact us if you would like further information or would like to work on any specific project.

 

SEARCH

PROPOSED STUDIES

Real-world effectiveness of allergen immunotherapy

PROPOSED STUDIES

Utilise routine care data to identify the optimum duration of antibiotics for respiratory infections
ACTIVE STUDIES

Clinical implications of combining antibiotics with usual care (oral steroids) for the management of asthma exacerbations
Characterisation of current asthma management practice and asthma-related morbidity
Implications of ICS prescription duration on asthma outcomes
Evaluate the prevalence of inappropriate SABA (excess) and LABA (monotherapy) prescribing in patients with asthma

ACTIVE STUDIES

Implementation of national recommendations for community acquired pneumonia in routine care
– Recommendations by the National Institute for Health and Care Excellence in the UK

PROPOSED STUDIES

Implications of steroid tailoring on treatment outcomes in patients with COPD managed in routine care

ACTIVE STUDIES

Evaluate the real-world prevalence of comorbidities in patients with COPD and their impact on COPD symptoms and quality of life

PROPOSED STUDIES

Evaluate the implications of single versus multiple device use on implementation of triple therapy in eligible patients with COPD managed in routine care
Device switching (e.g. from ICS/LABA DPI to pMDI)(s) to FP/FOR pMDIs (Transfform)
ACTIVE STUDIES

Characterisation of the path to idiopathic pulmonary fibrosis (IPF) and potential missed diagnostic opportunities

PROPOSED STUDIES

Characterisation of interstitial lung disease (ILD) diagnostic practice around the world and implications on diagnostic agreement and access to licensed therapies

ACTIVE STUDIES

Characterise the management of (and evaluate the implementation of guidelines for) acute and chronic rhinosinusitis in routine clinical practice

Asthma

PROPOSED STUDIES

Development of a Longitudinal Asthma Treatment Step Algorithm and Association with Asthma Outcomes
Investigate bronchiolitis in early childhood as a predictor of future and asthma

ACTIVE STUDIES

Utilise routine care data to develop a risk prediction model patients with asthma
Role of Exhaled Breath Temperature (EBT) in the monitoring of asthma

COMPLETED STUDIES

Blood eosinophilia as a predictor of future risk in asthma

PROPOSED STUDIES

Item reduce the EXACT (Exacerbations of Chronic Pulmonary Disease Tool) Questionnaire for improved exacerbation risk prediction (clinical use and self-(tele) monitoring)
Implications of a mixed asthma-COPD phenotype on natural history vs COPD
Evaluate the role of fractional exhaled nitric oxide (FeNO) as a biomarker in COPD
Implications of eosinopenia on future pneumonia risk in patients with COPD

ACTIVE STUDIES

Evaluate the potential role of blood eosinophils as a biomarker—predictor of future risk and / or treatment response—in COPD
Characterise the natural history of patients with alpha-1 antitrypsin deficiency in routine care patients with/without COPD
Role of Exhaled Breath Temperature (EBT) in the monitoring of COPD

COMPLETED STUDIES

Utilise routine care data to develop a risk prediction model patients with COPD
The effect of statins and/or beta blockers on COPD exacerbation frequency

ACTIVE STUDIES

Characterise the natural history of IPF vs non-IPF ILD in terms of FVC lung function decline
Utilise routine care data to identify predictors / red flags for idiopathic pulmonary fibrosis (IPF)

PROPOSED STUDIES

Evaluate the cardiovascular and neuropsychiatric risks of varenicline
Longterm safety of inhaled obstructive lung disease treatments and implications of patient age on side-effect profiles

ACTIVE STUDIES

Evaluate the cardiovascular risk profile of nicotine replacement therapy
Usage and safety of beta blockers in routine care patients with COPD and heart failure

COMPLETED STUDIES

Burden of oral steroid comorbidities in refractory asthma

PROPOSED STUDIES

Comparative effectiveness of triple therapy versus guideline recommended dual therapy (ICS/LABA and LAMA/LABA) alternatives in patients with COPD
Implications of steroid tailoring on treatment outcomes in patients with COPD managed in routine care

ACTIVE STUDIES

Comparative effectiveness of guideline recommended treatment options for patients with pre-school asthma / wheeze

COMPLETED STUDIES

Comparative effectiveness of Step three treatment options in children with asthma
Clinical predictors of prescribed step three treatment in paediatrics

PROPOSED STUDIES

Implications of ICS particle size on the management of routine care patients with a mixed asthma-COPD phenotype

ACTIVE STUDIES

A systematic review of the comparative effectiveness literature considering extra-fine particle ICS with licensed alternatives
The implications of particle size on ICS dose response in patients with asthma
Implications of ICS particle size on potential long-term asthma treatment-related side effects (e.g. metabolic and musculoskeletal comorbidities, pneumonia)

COMPLETED STUDIES

Comparative effectiveness of stepping-up asthma maintenance therapy as extrafine versus non-extrafine particle ICS
Comparative effectiveness of initiating asthma maintenance therapy as extrafine versus non-extrafine particle ICS
Comparative effectiveness of extrafine ICS + LABA versus non-extrafine ICS + LABA as step-up therapy for patients with uncontrolled asthma

Cost Effectiveness - COMPLETED STUDIES

Cost-effectiveness of initiating extrafine- versus non extrafine ICS for the management of asthma
Cost-effectiveness of asthma step-up therapy as an increased dose of small-particle inhaled corticosteroid or add-on long-acting beta2-agonist

Asthma - Smokers - COMPLETED STUDIES

Implications of ICS particle size for the management of asthma in patients with current / past smoking history

Asthma - Paediatrics - ACTIVE STUDIES

Comparative effectiveness of stepping up maintenance therapy as extra fine ICS versus fixed dose combination (non-extrafine) ICS/LABA therapy in routine care paediatric asthma management
Comparative effectiveness of extra-fine particle ICS compared with guideline recommended alternative treatment options for patients with pre-school asthma / wheeze

COMPLETED STUDIES

Comparative effectiveness of extrafine particle versus guideline recommended alternatives as first- and step-up maintenance therapy in children

COPD - COMPLETED STUDIES

Comparative effectiveness of extrafine versus non extrafine ICS for the management of routine care patients with COPD

Comorbidities - PROPOSED STUDIES

Implications of ICS particle size on the management of respiratory patients with comorbid GERD

ACTIVE STUDIES

Comparative effectiveness of spacers for the delivery of extrafine veruss non-extrafine particle ICS in asthma

Should you wish to address any of these needs through your own research, we would request that you please state in relevant grant applications and research publications that your work is “…responding to an REG-identified research need”. We would also ask you to please inform us of your study so that we can:

  • Include relevant links to your work via this site, for the benefit of the research community
  • Offer introductions and opportunities to work with REG collaborators (e.g. as part of an advisory steering committee)
  • Provide details of your entitlement to complimentary ADEPT review.

The following list of research opportunities reflects areas of unmet research need within respiratory and allergic airways disease that real-life research methodologies (observational studies and pragmatic trials) are well positioned to address. It is intended as a dynamic list of research opportunities that have been identified by REG's expert members and working groups as having important value to the field. All investigators responding to one of the research needs will be eligible for a complimentary review of their study protocol by the expert, independent Anonymised Data Ethics and Protocol Transparency (ADEPT) Committee, which convenes under the auspices of the REG.

Where the REG is currently responding to the identified research gap, relevant links to REG's activities have been provided.

Tag allows you to search by research need, as listed below. Each need is divided into categories that allows you to view projects by status. You may search with either or both of these parameters, or type a keyword into the search box to find relevant projects from REG.

If you're looking for a project for your own research, you can filter by proposed projects and use the keyword option to narrow your search. Contact us if you would like further information or would like to work on any specific project.

[searchandfilter fields="search,category,types, select,post_tag"][vc_text_separator title="CLINICAL PRACTICE"][vc_tta_accordion active_section="V"][vc_tta_section title="1. Characterise current routine care disease epidemiology and burden for respiratory, allergic and obstructive airways disease outcomes" tab_id="1469450571571-7d2192d4-795a"]PROPOSED STUDIES

[/vc_tta_section][vc_tta_section title="2. Characterise current routine care prescribing practices (diagnostic and management) and their implications for respiratory and allergic airways disease outcomes" tab_id="1469450571643-93112ef1-ea37"][vc_text_separator title="Allergy"]PROPOSED STUDIES

[vc_text_separator title="Antibiotic Prescribing"]PROPOSED STUDIES

[vc_text_separator title="Asthma"]ACTIVE STUDIES

[vc_text_separator title="Community Acquired Pneumonia"]ACTIVE STUDIES

[vc_text_separator title="COPD"]

PROPOSED STUDIES

ACTIVE STUDIES

[vc_text_separator title="Devices"]PROPOSED STUDIES

[vc_text_separator title="Interstitial Lung Disease"]ACTIVE STUDIES

PROPOSED STUDIES

[vc_text_separator title="Rhinitis & Rhinosinusitis"]ACTIVE STUDIES

[/vc_tta_section][vc_tta_section title="3. Utilise routinely collected data to describe disease characteristics associated with future risk in respiratory and allergic airways disease" tab_id="1469456481599-299bb79d-d807"][vc_text_separator title="Asthma"]

PROPOSED STUDIES

ACTIVE STUDIES

COMPLETED STUDIES

[vc_text_separator title="COPD"]PROPOSED STUDIES

ACTIVE STUDIES

COMPLETED STUDIES

[vc_text_separator title="Interstitial Lung Disease"]ACTIVE STUDIES

[/vc_tta_section][vc_tta_section title="4. Assess the real-world safety profile of licensed pharmacological interventions for / as used in patients with respiratory and allergic airway diseases, and associated characteristics of the patients, the disease, the ecology of care" tab_id="1469460152950-5eb92667-f6ca"]PROPOSED STUDIES

ACTIVE STUDIES

COMPLETED STUDIES

[/vc_tta_section][vc_tta_section title="5. Evaluate the comparative effectiveness of treatments (guideline-recommended / not recommended but frequently used) in respiratory and allergic airways disease, and associated characteristics of the patients, the disease, the ecology of care" tab_id="1469460861954-999be5a0-f8b4"][vc_text_separator title="COPD"]PROPOSED STUDIES

[vc_text_separator title="Paediatric Asthma"]ACTIVE STUDIES

COMPLETED STUDIES

[/vc_tta_section][vc_tta_section title="6. Understand the role of maintenance inhaled therapy particle size on outcomes in respiratory and allergic airways disease" tab_id="1470649599584-de7ab356-ec41"][vc_text_separator title="Asthma - General"]PROPOSED STUDIES

ACTIVE STUDIES

COMPLETED STUDIES

  • Comparative effectiveness of stepping-up asthma maintenance therapy as extrafine versus non-extrafine particle ICS
  • Comparative effectiveness of initiating asthma maintenance therapy as extrafine versus non-extrafine particle ICS
  • Comparative effectiveness of extrafine ICS + LABA versus non-extrafine ICS + LABA as step-up therapy for patients with uncontrolled asthma

[vc_text_separator title="Asthma - Cost Effectiveness"]COMPLETED STUDIES

[vc_text_separator title="Asthma - Smokers"]COMPLETED STUDIES

  • Implications of ICS particle size for the management of asthma in patients with current / past smoking history

[vc_text_separator title="Asthma - Paediatrics"]ACTIVE STUDIES

COMPLETED STUDIES

[vc_text_separator title="COPD"]COMPLETED STUDIES

  • Comparative effectiveness of extrafine versus non extrafine ICS for the management of routine care patients with COPD

[vc_text_separator title="Comorbidities"]PROPOSED STUDIES

ACTIVE STUDIES

[/vc_tta_section][/vc_tta_accordion][vc_tta_accordion active_section="Y" collapsible_all="true"][vc_tta_section title="7. Improve understanding of medication adherence behaviours (including inhaler device challenges) in respiratory and allergic airways disease, their implications on clinical and health economic outcomes and optimised management options" tab_id="1473869115513-05387465-d18e"]PROPOSED STUDIES

ACTIVE STUDIES

COMPLETED STUDIES

[/vc_tta_section][vc_tta_section title="8. Understand the clinical and cost implications of comorbidities (and their treatments) in patients with respiratory and allergic airway diseases" tab_id="1473869115514-0f2192da-d465"]PROPOSED STUDIES

ACTIVE STUDIES

COMPLETED STUDIES

[/vc_tta_section][/vc_tta_accordion][vc_text_separator title="ADVOCACY & QUALITY STANDARDS"][vc_tta_accordion active_section="Y" collapsible_all="true"][vc_tta_section title="9. Provide methodological support for high quality real-world research" tab_id="1473870004388-ffead251-1d6a"]PROPOSED STUDIES

ACTIVE STUDIES

[/vc_tta_section][vc_tta_section title="10. Define, refine and validate clinical tools for the real-world management of respiratory and allergic airways disease" tab_id="1473870004389-6021702a-fb06"]PROPOSED STUDIES

  • Validation of future risk prediction models using alternative national and international databases

ACTIVE STUDIES

[/vc_tta_section][vc_tta_section title="11. Define, refine and validate tools (e.g. databases, indicators) for real-world research on respiratory and allergic airways disease" tab_id="1473870042241-5f4c081d-8d5c"]PROPOSED STUDIES

ACTIVE STUDIES

[/vc_tta_section][vc_tta_section title="12. Guide the development of technology-based solutions (TBS) with clinical utility for respiratory and allergic airway diseases" tab_id="1473870044818-66bed981-f3c0"]PROPOSED STUDIES

[/vc_tta_section][/vc_tta_accordion]Should you wish to address any of these needs through your own research, we would request that you please state in relevant grant applications and research publications that your work is "...responding to an REG-identified research need". We would also ask you to please inform us of your study so that we can:

  • Include relevant links to your work via this site, for the benefit of the research community
  • Offer introductions and opportunities to work with REG collaborators (e.g. as part of an advisory steering committee)
  • Provide details of your entitlement to complimentary ADEPT review.